-
Featured Authors
Inside BIO
- Big Red Biotech blog
- Biocentury
- BiotechBlog
- Bruce Booth
- Fierce Biotech
- Get the Facts from Farmer Gene
- GMO Pundit
- Harvest Public Media
- In Vivo Blog
- Industrial Biotechnology and Climate Change
- Partnership to Improve Patient Care
- Patent Baristas
- Patently BIOtech
- Pharmalot
- Xconomy – Life Sciences
- YouTube – The BIOchannel
Category Archives: Inside BIO Industry Analysis
Biotech IPO Update for May 18th, 2011
There are now eight biotech IPOs for 2011, bringing the total for the recent US IPO window to 28. Post-IPO performance is finally picking up with the median return at +14% for these 28 IPOs. Advanced BioHealing was scheduled to IPO this week, but Shire (SHGPY) came in with a $750M offer to buy the company. Sagent Pharmaceuticals (SGNT) was the most recent IPO, back in April. Sagent is a specialty pharma company selling injectable Read More >
Nasdaq Biotech Index re-ranking for next Monday
Twice a year, in May and November, the NASDAQ OMX Group re-ranks the closely watched Nasdaq Biotechnology Index (NBI). This Monday (May 23rd), six companies will be added to the Nasdaq Biotech index and two will be removed. The additions are Achillion Pharmaceuticals (ACHN), AVEO Pharmaceuticals (AVEO), Columbia Laboratories (CBRX), ISTA Pharmaceuticals (ISTA), Pacific Biosciences (PACB) and Zalicus (ZLCS). The two companies to be removed from the NBI are Biodel (BIOD) and China Sky One Read More >
IPO Update – April 5th, 2011
The six biotech IPOs of 2011 have followed 2010′s IPO trends; all took significant haircuts getting out the door and most are performing modestly. The median downward adjustment in the amount raised for 2011′s biotech IPOs stands at -31%, the average is at -33%. These companies have raised a median and mean amount of $49M and $54M, respectively. Despite the lukewarm IPO reception biotech stocks have faced in the U.S., two more U.S. companies have filed to go public since the close of 2010. Specialty pharmaceutical Read More >
The BTK buyout
Remember this BTK post we wrote back in February of 2010? Well, we thought it was time to revisit the makeup of the BTK index (NYSE Arca Biotechnology Index). Five of the 20 companies that comprised the index in February of last year have either been acquired or are facing acquisition. That means 25% of the entire index has been snapped up in a little over a year (Table 1). Millipore (MIL) and OSI Pharmaceuticals (OSIP) acquired in 2010 by Merck KGaA and Astellas, respectively, have already Read More >
BIO Europe Spring – State of the Biotech Industry
BIO Industry Analysis provided opening remarks at BIO Europe Spring in Milan, Italy, this morning. Dr. John Craighead shared the highlights of BIO’s latest industry update: click here for the slides in pdf format.
